<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rotavirus vaccines (RV1 and RV5): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rotavirus vaccines (RV1 and RV5): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rotavirus vaccines (RV1 and RV5): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10273" href="/d/html/10273.html" rel="external">see "Rotavirus vaccines (RV1 and RV5): Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2553110"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Rotarix;</li>
<li>RotaTeq</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914200"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rotarix;</li>
<li>RotaTeq</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F2687131"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Live Virus</span></li></ul></div>
<div class="block dop drugH1Div" id="F2554561"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consult CDC/ACIP annual immunization schedules or National Advisory Committee on Immunization (NACI) guidelines (Canada) for additional information, including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2022]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">The ACIP recommends completing the vaccine series with the same product whenever possible. If continuing with same product will cause vaccination to be deferred, or if product used previously is unknown, vaccination should be completed with the product available. If RotaTeq was used in any previous doses, or if the specific product used was unknown, a total of 3 doses should be given (CDC/ACIP [Cortese 2009]).</p>
<p style="text-indent:-2em;margin-left:6em;">Rotarix: <b>Note:</b> Product is available in 2 formulations, a ready-to administer oral dose formulation (oral dosing applicator only) and a vial that requires reconstitution prior to administration; dosing varies based on formulation; use caution.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Ready-to-administer formulation</i>
<i>(does not require reconstitution):</i> Infants 6 to 24 weeks of age: Oral: 1.5 mL per dose for 2 doses; the first dose may be administered beginning at 6 weeks of age, and the second dose should be administered ≥4 weeks after the first. The 2-dose series should be completed by 24 weeks of age.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Powder for reconstitution (vial for oral use; requires reconstitution):</i> Infants 6 to 24 weeks of age: Oral: 1 mL per dose for 2 doses; the first dose may be administered beginning at 6 weeks of age, and the second dose should be administered ≥4 weeks after the first. The 2-dose series should be completed by 24 weeks of age.</p>
<p style="text-indent:-2em;margin-left:6em;">RotaTeq: Infants 6 to 32 weeks of age: Oral: 2 mL per dose for 3 doses, with the first dose given at 6 to 12 weeks of age, followed by subsequent doses at 4- to 10-week intervals. Administer all doses by 32 weeks of age.</p>
<p style="text-indent:-2em;margin-left:4em;">ACIP recommendations (CDC/ACIP [Cortese 2009]): The first dose can be given at 6 weeks through 14 weeks 6 days of age. The series should not be started in infants ≥15 weeks. The final dose in the series should be administered by 8 months 0 days of age. The minimum interval between doses is 4 weeks. Rotarix should be given in 2 doses administered at 2 and 4 months of age. RotaTeq should be given in 3 doses administered at 2, 4, and 6 months of age. For infants inadvertently administered rotavirus vaccine at ≥15 weeks of age, the vaccine series may be completed according to schedule. Infants who have had rotavirus gastroenteritis before getting the full course of vaccine should still initiate or complete the recommended schedule; initial infection provides only partial immunity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="030231b8-f8a7-4a85-8830-e75f8b3f4505">Catch-up immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catch-up immunization:</b> ACIP recommendations (CDC/ACIP [Cortese 2009]): Oral: <b>Note:</b> Do not restart the series. If doses have been given, begin the catch-up schedule at the applicable dose number and separate doses by 4 weeks; total of 3 doses. The series should not be started in infants ≥15 weeks 0 days of age. The final dose in the series should be administered by 8 months 0 days of age. For infants inadvertently administered rotavirus vaccine at ≥15 weeks of age, the vaccine series should be completed according to schedule and prior to 8 months 0 days of age. If RotaTeq was used in any previous doses, or if the specific product used was unknown, a total of 3 doses should be given.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159966"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159967"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F2553122"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in infants.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (4% to 24%), vomiting (3% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Irritability (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (1%), nasopharyngitis (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Gastrointestinal: Intestinal intussusception</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Kawasaki syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hematochezia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Immune thrombocytopenia (Siddiqui 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p></div>
<div class="block coi drugH1Div" id="F2553118"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to rotavirus vaccine or any component of the formulation; history of uncorrected congenital malformation of the GI tract (such as Meckel diverticulum) that would predispose the infant for intussusception (Rotarix only); history of intussusception; severe combined immunodeficiency disease</p></div>
<div class="block war drugH1Div" id="F2553119"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Intussusception: An increased risk of intussusception was observed with a previously licensed rotavirus vaccine. Cases have been noted in postmarketing reports and a temporal association has been observed in postmarketing observational studies with current vaccines. Cases were noted within 21 to 31 days of the first dose, with a clustering of cases within the first 7 days following administration. An increased risk was also observed within the first 7 days of the second dose. Use of RotaTeq and Rotarix is contraindicated with a history of intussusception. In postmarketing experience, intussusception resulting in death following a second dose has been reported following a history of intussusception after the first dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in infants with history of GI disorders, acute mild GI illness, chronic diarrhea, failure to thrive, congenital abdominal disorders, and abdominal surgery; vaccine may be used with controlled gastroesophageal reflux disease. ACIP recommends that the vaccine should generally not be administered to infants with acute moderate or severe gastroenteritis (CDC/ACIP [Cortese 2009]). Rotarix is contraindicated with a history of an uncorrected congenital malformation of the GI tract; RotaTeq and Rotarix are contraindicated with a history of intussusception.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or non-live) for which a person is eligible at a visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand name is unavailable (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adults: Not intended for use in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunocompromised family members: Virus from live virus vaccines may be transmitted to nonvaccinated contacts; use with caution in the presence of immunocompromised family members. Viral shedding occurs within the first weeks of administration; peak viral shedding generally occurs ~7 days after the first dose. The ACIP recommends vaccination of infants living in households with persons who are immunocompromised (CDC/ACIP [Cortese 2009]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunocompromised infants: Severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) generally should not receive live vaccines; may have a reduced response to vaccination or may have an adverse event secondary to replication. May be administered with topical corticosteroids or inhaled steroids, or to infants with primary and acquired immunodeficiencies (including HIV/AIDS, cellular immune deficiencies, hypogammaglobulinemic and dysgammaglobulinemic states). Household and close contacts of persons with altered immunocompetence may receive most age-appropriate vaccines. Live vaccines should be administered ≥4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for at least 3 months after immunosuppressive therapy (ACIP [Kroger 2023]). Specific recommendations for use of this vaccine in immunocompromised patients as well as contacts of immunocompromised patients are available from the IDSA (IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Some packaging may contain natural latex/natural rubber.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Administration errors have been reported. This vaccine is for oral administration only; doses inadvertently administered by injection are not considered valid and an oral replacement dose should be given according to the appropriate age and schedule (CDC [Hibbs 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Postexposure prophylaxis: Information is not available for use in postexposure prophylaxis.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878698"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Safety data with Rotarix in preterm neonates (≤36 weeks GA) showed a similar incidence of serious adverse effects compared to placebo (5.2% vs 5%); no deaths or cases of intussusception were reported in this population. Eye splashes to the provider, parent, or infant have been reported; to minimize risk of coughing, sneezing, and spitting, administer gently inside the cheek (CDC [Hibbs 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">Although the incidence is very low, Kawasaki disease has been observed more frequently in rotavirus vaccine (Rotarix) treatment groups than placebo; based on data from 16 trials, Kawasaki disease was reported in 0.035% of recipients (n=18) of Rotarix group and 0.021% of placebo recipients (n=9). Specific to the placebo-controlled trials, Kawasaki disease was reported in 17 recipients of Rotarix and 9 placebo recipients (RR, 1.71; 95% CI, 0.71 to 4.38). Eleven percent of cases were reported within 30 days postvaccination (range: 3 days to 19 months after vaccine dose). Direct causality has not been established; patients with suspicious clinical presentation should be monitored closely with appropriate diagnostic workup.</p></div>
<div class="block foc drugH1Div" id="F2554565"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder, for suspension, oral [preservative free; human derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Rotarix: G1P[8] ≥10<sup>6</sup> CCID<sub>50</sub> per 1 mL [contains sorbitol, sucrose; supplied with diluent which may contain natural rubber/natural latex in packaging]</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, oral [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Rotarix: G1P[8] ≥10<sup>6</sup> CCID<sub>50</sub> per 1.5 mL [contains sucrose; packaging of applicators contain nautral rubber latex; human derived]</p>
<p style="text-indent:-2em;margin-left:4em;">RotaTeq: G1 ≥2.2 x 10<sup>6</sup> infectious units, G2 ≥2.8 x 10<sup>6</sup> infectious units, G3 ≥2.2 x 10<sup>6</sup> infectious units, G4 ≥2 x 10<sup>6</sup> infectious units, and P1A [8] ≥2.3 x 10<sup>6</sup> infectious units per 2 mL (2 mL) [contains sucrose; bovine and human derived]</p></div>
<div class="block geq drugH1Div" id="F2553112"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52914201"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;margin-left:0em;margin-top:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, oral [human derived]:</p>
<p style="text-indent:-2em;margin-left:4em;">Rotarix: ≥10<sup>6</sup> CCID<sub>50</sub> per 1.5 mL (1.5 mL)</p></div>
<div class="block admp drugH1Div" id="F52614168"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Oral use only; <b>not for injection</b>. May be administered before or after food, milk, or breast milk. To avoid potential eye splashes caused by coughing, sneezing, and spitting, administer gently inside the cheek (CDC [Hibbs 2014]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the Rotarix prescribing information states that a regurgitated or spit out dose may be repeated, the ACIP, AAP, and the RotaTeq prescribing information do not recommend readministering doses. Any remaining dose(s) should be administered on schedule (AAP 2009; ACIP [Kroger 2022]; CDC/ACIP [Cortese 2009]).</p>
<p style="text-indent:-2em;margin-left:2em;">Rotarix: <b>Note: </b>The ready-to-administer Rotarix formulation is provided in an oral dosing applicator with an applicator tip cap. The tip cap presents a potential choking hazard and should be removed prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ready-to-administer formulation (does not require reconstitution)</i>: Remove tip cap from oral dosing applicator. Infant should be in reclining position. Using oral applicator, administer contents into infant's inner cheek. Dispose of applicator and vaccine vial in biologic waste container.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Vial for reconstitution and oral dosing applicator presentation:</i> Reconstitute vaccine prior to administration. Infant should be in reclining position. Using oral applicator, administer contents into infant's inner cheek. Dispose of applicator and vaccine vial in biologic waste container.</p>
<p style="text-indent:-2em;margin-left:2em;">RotaTeq: Gently squeeze dose from ready-to-use dosing tube into infant's mouth toward the inner cheek until dosing tube is empty. After use, dispose of the empty tube and cap in a biologic waste container. Do not mix or dilute vaccine with any other vaccine or solution.</p></div>
<div class="block sts drugH1Div" id="F2554554"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Rotarix:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral dosing applicator only formulation (does not require reconstitution): Store in original package under refrigeration at 2°C to 8°C (36°F to 46°F); do not freeze. Protect vaccine from light; discard vaccine if frozen.</p>
<p style="text-indent:-2em;margin-left:4em;">Vial and oral dosing applicator formulation (requires reconstitution): Store intact vials under refrigeration at 2°C to 8°C (36°F to 46°F); diluent may be stored under refrigeration at 2°C to 8°C (36°F to 46°F) or at room temperature up to 25°C (77°F). Protect vaccine from light; discard diluent if frozen. Following reconstitution, may be refrigerated at 2°C to 8°C (36°F to 46°F) or stored at room temperature up to 25°C (77°F) for up to 24 hours. Discard if frozen.</p>
<p style="text-indent:-2em;margin-left:2em;">RotaTeq: Store and transport under refrigeration at 2°C to 8°C (36°F to 46°F). Use as soon as possible once removed from refrigerator. Protect from light. Canadian labeling suggests that once the vaccine is removed from refrigeration, it may be stored at temperatures up to 25°C (77°F) for up to 4 hours; do not freeze. Protect from light.</p></div>
<div class="block meg drugH1Div" id="F25734138"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Frotavirus.html&amp;token=u1LiC%2FORPmfgHx7bkN1uD9T0n%2Fz6dSEA0rZmFLG0OHoY2G6ug4BjjOa8MixiGpKKzmjIQO%2B%2BxqOIt37eGnO%2FwxF0UBbr9l7ytcTw5usz2Zc%3D&amp;TOPIC_ID=13075" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/rotavirus.html</a>.</p></div>
<div class="block usep drugH1Div" id="F53569953"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Routine immunization to prevent rotavirus gastroenteritis caused by serotypes G1, G3, G4, and G9 (Rotarix) or serotypes G1, G2, G3, G4, and G9 (RotaTeq) (Rotarix: FDA approved in ages 6 to 24 weeks; RotaTeq: FDA approved in ages 6 to 32 weeks).</p>
<p style="text-indent:0em;margin-top:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of all infants (CDC/ACIP [Cortese 2009]).</p></div>
<div class="block mst drugH1Div" id="F24066621"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Rotavirus vaccines (Rotarix and RotaTeq) are only available for <b>ORAL</b> administration. The live oral rotavirus vaccines have been inadvertently administered as an injection, thereby making the vaccine ineffective (ISMP 2014). Avoid the administration of oral rotavirus vaccines as an injection. An oral dose should still be given if the dose was inadvertently administered as an injection (CDC [Hibbs 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">Rotarix is available as 2 formulations; one requires dilution prior to administration and the other is a ready-to-administer prefilled oral syringe.</p>
<p style="text-indent:-2em;margin-left:4em;">The ready-to-administer Rotarix formulation is provided in an oral dosing applicator with an applicator tip cap. The tip cap presents a potential choking hazard and should be removed prior to administration (ISMP 2022).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300016"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2554552"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Cladribine may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Non-US labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment. US labeling states that safety and effectiveness of live vaccines administered with dimethyl fumarate has not been assessed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Etrasimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May diminish the therapeutic effect of Vaccines (Live).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccines-associated infection may be increased. Teplizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezepelumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tildrakizumab: May enhance the adverse/toxic effect of Vaccines (Live). The risk for contracting an infection from the vaccine may be increased. Tildrakizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tralokinumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: It is preferable to administer live vaccines simultaneously with tuberculin tests. If a live vaccine has been recently administered, the tuberculin skin test should be administered 4 to 6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F2554562"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be administered before or after food, milk, or breast milk.</p></div>
<div class="block pri drugH1Div" id="F3274446"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Rotavirus vaccine is not indicated for use in women of reproductive age. Infants living in households with pregnant women may be vaccinated (CDC/ACIP [Cortese 2009]).</p></div>
<div class="block mopp drugH1Div" id="F57599733"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs and symptoms of intussusception (eg, abdominal pain, vomiting).</p></div>
<div class="block pha drugH1Div" id="F2554555"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A live vaccine; replicates in the small intestine and promotes active immunity to rotavirus gastroenteritis. Rotarix is specifically indicated for prevention of rotavirus gastroenteritis caused by serotypes G1, G3, G4, and G9 and RotaTeq is specifically indicated for prevention of rotavirus gastroenteritis caused by serotypes G1, G2, G3, G4, and G9. However, these vaccines may provide immunity to other rotavirus serotypes.</p></div>
<div class="block phk drugH1Div" id="F2554557"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> There is no established relationship between antibody response and protection against gastroenteritis.</p>
<p style="text-indent:-2em;margin-left:2em;">Seroconversion:</p>
<p style="text-indent:-2em;margin-left:4em;">Rotarix: Antirotavirus IgA antibodies were noted 1 to 2 months following completion of  the 2-dose series in 77% to 87% of infants.</p>
<p style="text-indent:-2em;margin-left:4em;">RotaTeq:  A threefold increase in antirotavirus IgA was noted following completion of the 3-dose regimen in 93% to 100% of infants.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Following administration of rotavirus vaccine, efficacy of protecting against any grade of rotavirus gastroenteritis through two seasons was 71% to 79%</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539971"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq | Vacina rotavirus | Vacina rotavirus humano G1P (Atenuada)</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Luo te wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotasiil | Rotateq</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Rotasure | Rotateq | Rotavac | Rotavac 5D</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotarix prefilled | Rotateq</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Rotasiil | Rotateq</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotasiil Liquid | Rotateq</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Rotateq</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq | Rotavac</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Rotavin M1</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Rotarix | Rotateq | Rotavac 5D</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Rotarix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19332437">
<a name="19332437"></a>American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine. <i>Pediatrics</i>. 2009;123(5):1412-1420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/19332437/pubmed" id="19332437" target="_blank">19332437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19194371">
<a name="19194371"></a>Cortese MM, Parashar UD; Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in <i>MMWR Recomm Rep</i>. 2010;59(33):1074]. <i>MMWR Recomm Rep</i>. 2009;58(RR-2):1-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/19194371/pubmed" id="19194371" target="_blank">19194371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24476980">
<a name="24476980"></a>Hibbs BF, Miller ER, Shimabukuro T; Centers for Disease Control and Prevention. Notes from the field: rotavirus vaccine administration errors—United States, 2006-2013. <i>MMWR Morb Mortal Wkly Rep</i>. 2014;63(4):81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/24476980/pubmed" id="24476980" target="_blank">24476980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice. Oral vaccine mistakenly given by injection. ISMP Medication Safety Alert; February 13, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2">
<a name="ISMP.2"></a>Institute for Safe Medication Practice (ISMP). Rotarix cap could pose a choking hazard. <i>ISMP Medication Safety Alert!</i>; December 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.2">
<a name="Kroger.2"></a>Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed December 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated 2023. Accessed April 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21293327">
<a name="21293327"></a>National Center for Immunization and Respiratory Diseases (NCIRD). General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2011;60(2):1-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/21293327/pubmed" id="21293327" target="_blank">21293327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JAMA.1">
<a name="JAMA.1"></a>Oral Rotavirus Vaccines Sometimes Mistaken for Injectables. <i>JAMA</i>. 2014;311(10):1006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al. Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467670">
<a name="18467670"></a>Reisinger KSm Block SL, Characteristics of an Ideal Rotavirus Vaccine. <i>Clin Pediatr (Phila)</i>. 2008;47(6):555-563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/18467670/pubmed" id="18467670" target="_blank">18467670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rotarix.2">
<a name="Rotarix.2"></a>Rotarix (rotavirus vaccine, live, oral) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rotarix.1">
<a name="Rotarix.1"></a>Rotarix (rotavirus vaccine, live, oral) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rotarix.3">
<a name="Rotarix.3"></a>Rotarix (rotavirus vaccine, live, oral) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RotaTeq.1">
<a name="RotaTeq.1"></a>RotaTeq (rotavirus vaccine) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20054872">
<a name="20054872"></a>Siddiqui AH, Chitlur MB. Immune thrombocytopenic purpura in a 5-month-old female with rotavirus infection. <i>Pediatr Blood Cancer</i>. 2010;54(4):633. doi:10.1002/pbc.22368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/20054872/pubmed" id="20054872" target="_blank">20054872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Soriano-Gabarro.1">
<a name="Soriano-Gabarro.1"></a>Soriano-Gabarro M, Verstraeten T, Gillard P, et al. Potential Impact of Rotarix According to Rotavirus Type Distribution. <i>Pediatr Infect Dis J</i>. 2008;27(1):28-32.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18037080">
<a name="18037080"></a>Vesikari T, Karvonen A, Prymula R, et al. Efficacy of Human Rotavirus Vaccine Against Rotavirus Gastroenteritis During the First 2 Years of Life in European Infants: Randomised, Double-Blind Controlled Study. <i>Lancet.</i> 2007;370(9601):1757-1763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/18037080/pubmed" id="18037080" target="_blank">18037080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16394299">
<a name="16394299"></a>Vesikari T, Matson DO, Dennehy P, et al. Safety and Efficacy of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine. <i>N Engl J Med</i>. 2006;354(1):23-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rotavirus-vaccines-rv1-and-rv5-pediatric-drug-information/abstract-text/16394299/pubmed" id="16394299" target="_blank">16394299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 13075 Version 190.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
